Center-Authored Papers

Filters: Author is Ramjee, Gita  [Clear All Filters]
2008
Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B.  2008.  The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.. Journal of acquired immune deficiency syndromes (1999). 47(1):93-100. Abstract
2012
Chirenje ZM, Mâsse BR, Maslankowski LA, Ramjee G, Coletti AS, Tembo TN, Magure TM, Soto-Torres L, Kelly C, Hillier S et al..  2012.  Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel.. Journal of the International AIDS Society. 15(2):17376. Abstract
Dezzutti CS, Richardson BA, Marrazzo JM, Tugetman J, Ramjee G, Taha T, Chirenje ZM, Abdool Karim SS, Hillier SL, Herold BC.  2012.  Mucosal Escherichia coli Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial.. The Journal of infectious diseases. 206(12):1931-5. Abstract
2013
Richardson BA, Kelly C, Ramjee G, Fleming T, Makanani B, Roberts S, Musara P, Mkandawire N, Moench T, Coletti A et al..  2013.  Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: A comparison of the two control arms of HPTN 035.. Journal of acquired immune deficiency syndromes (1999). Abstract
2014
Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodi N, Kasaro MP, Ramjee G, Hoffman IF, Abdool Karim SS.  2014.  Bacterial Vaginosis and the Risk of Trichomonas vaginalis Acquisition Among HIV-1-Negative Women.. Sexually transmitted diseases. 41(2):123-8. Abstract
Guffey BM, Richardson B, Husnik M, Makanani B, Chilongozi D, Yu E, Ramjee G, Mgodi N, Gomez K, Hillier SL et al..  2014.  HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.. Sexually transmitted infections. Abstract
2015
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L et al..  2015.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.. The New England journal of medicine. 372(6):509-18. Abstract
Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje MZ, Bunge K, Ramjee G, Nair G, Palanee-Phillips T et al..  2015.  Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study.. The lancet HIV. 2(7):e279-e287. Abstract
Balkus JE, Nair G, Montgomery ET, Mishra A, Palanee-Phillips T, Ramjee G, Panchia R, Selepe P, Richardson BA, Chirenje ZM et al..  2015.  Age-Disparate Partnerships and Risk of HIV-1 Acquisition among South African Women Participating in the VOICE Trial.. Journal of acquired immune deficiency syndromes (1999). Abstract
2016
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Kiweewa FM, Nair G, Mhlanga F et al..  2016.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.. The New England journal of medicine. Abstract
Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, Makanani B, Reid C, Martinson F, Soto-Torres L et al..  2016.  Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.. Contraception. 93(1):25-31. Abstract
Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, Makanani B, Reid C, Martinson F, Soto-Torres L et al..  2016.  Corrigendum to "oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial" [contraception 2016; 93 (1): 25-31].. Contraception. 94(1):95.
Kasaro MP, Husnik MJ, Chi BH, Reid C, Magure T, Makanani B, Tembo T, Ramjee G, Maslankowski L, Rabe L et al..  2016.  Impact of targeted counseling on reported vaginal hygiene practices and bacterial vaginosis: the HIV Prevention Trials Network 035 study.. International journal of STD & AIDS. Abstract
2017
Riddler SA, Husnik M, Ramjee G, Premrajh A, Tutshana BO, Pather A, Siva S, Jeenarain N, Nair G, Selepe P et al..  2017.  HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.. PloS one. 12(6):e0178594. Abstract